Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients

Annals of Internal Medicine

Volumn 124, Issue 6, 1996, Pages 573-576

  Trapnell, Carol Braun ^a   Narang, Prem K ^b   Li, Ronald ^c   Lavelle, James P ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b PFIZER INC   (United States)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FLUCONAZOLE; RIFABUTIN; ZIDOVUDINE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030003529     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-6-199603150-00006     Document Type: Article

References (19)

1. Leoung GS, Feigal DW Jr, Montgomery AB, Corkery K, Wardlaw L, Adams M, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial N Engl J Med 1990,323:769-75.
2. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group protocol 021 N Engl J Med. 1992,327.1842-8.
3. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group N Engl J Med 1995,332:693-9.
4. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS N Engl J Med. 1993,329:828-33
5. Spector SA, McKinley G, Drew WL, Stempien MJ, for the Syntex Ganciclovir Study Group. A randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons [Abstract]. Abstracts of the 2nd National Conference on Human Retroviruses 1995,1.55
6. Powderly WG, Finkelstein DM, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection NIAID AIDS Clinical Trials Group N Engl J Med. 1995,332:700-5
7. Morrow JD. Fluconazole a new triazole antifungal agent Am J Med Sci 1991,302.129-32
8. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, et al. Effects of imidazole derivatives on cytochrome p450 from human hepatocytes in primary culture FASEB J. 1992,6.752-8
9. Honig PK, Wortham DC Zamani K, Conner DP, Mullin JC, Cantilena LR Jr. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences JAMA 1993,269:1513-8
10. Monahan BP, Ferguson CL, Killeavy ES. Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use JAMA 1990,264:2788-90
11. Frank MO. Graham MB, Wispelway B. Rifabutin and uveitis [Letter] N Engl J Med 1994,330 868.
12. Fuller JD, Stanfield LE, Craven DE. Rifabutin prophylaxis and uveitis [Letter] N Engl J Med 1994,330:1315-6
13. Shafran SD, Deschênes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network [Letter]. N Engl J Med. 1994,330 438-9.
14. Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis Ann Intern Med 1994,121 510-2
15. Narany PK, Trapnell CB, Schoenfelder JE, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis [Letter]. N Engl J Med. 1994,330.1316-7
16. Foulds G, Brennan DR, Wajszczuk C, Catanzaro A, Garg DC, Knopf W, et al. Fluconazole penetration into cerebrospinal fluid in humans J Clin Pharmacol 1988;28:363-6.
17. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biologic fluids by high-performance liquid chromatography (HPLC) Pharm Res 1991;8:1434-40
18. Swarbrick J. Noncompartmental analysis based on statistical moment theory In. Gibaldi M, Perner D, eds Pharmacokinetics. 2d ed New York: Marcel Dekker, 1982:409-16
19. Cocchiara G, Strolin Benedetti M, Vicario GP, Ballabio M, Gioia B, Vioglio S, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers Xenobiotica 1989;19:769-80